Acrux Secures $1.6 Million Placement to Back Female Testosterone Trials

Placement Highlights and Investor Appetite

Acrux Limited (ASX:ACR) has successfully raised $1.6 million through a share placement priced at 0.95 cents per share, representing a 13.6% discount to its last traded price. The placement attracted binding commitments totalling $2.6 million but was scaled back by $1.0 million, reflecting solid investor interest yet a measured approach by Acrux to manage dilution.

The company plans to issue unlisted attaching options on a one-for-two basis to placement participants, subject to shareholder approval. These options carry an exercise price of 1.8 cents and a three-year expiry, potentially sweetening the deal for investors and aligning incentives with Acrux’s medium-term growth prospects.

Capital Deployment Towards Clinical Development

Proceeds from the placement will fund Acrux’s ongoing Phase III clinical trials for its female testosterone therapy targeting hypoactive sexual desire dysfunction (HSDD). This program underpins Acrux’s strategic pivot from generics to hormone replacement therapies, aiming to capture a sizeable opportunity in a market projected to reach nearly $3 billion in the US by 2030.

CEO John Warmbrunn emphasised the strong shareholder support and highlighted the company’s advancement towards a co-development agreement with an international partner, a move designed to accelerate regulatory approval and commercialisation. The specifics of this partnership remain under wraps, but the collaboration could be a critical catalyst for Acrux’s next growth phase.

Strategic Context and Market Positioning

This capital raise builds on Acrux’s recent strategic initiatives, including expanding its topical generics portfolio in the US and prioritising hormone replacement therapies. Earlier divestments of non-core assets have freed resources for this focus, as reflected in their solid revenue growth and increased cash reserves reported earlier in the year.

The attaching options offered to placement participants and lead manager Alpine Capital, who will receive options on similar terms, signal confidence in the company’s valuation trajectory, while also providing a mechanism to manage immediate dilution. However, shareholder approval for these options is pending, with a meeting expected in July 2026.

Acrux’s emphasis on female testosterone is consistent with its recent strategic disclosures, particularly its co-development strategy targeting the $2.9B female testosterone market, which has garnered attention for addressing a significant unmet medical need.